<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Epidemiological studies have consistently reported inverse associations between <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) and oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, but few have investigated associations with the precursor lesion, <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To investigate the relationship between <z:chebi fb="1" ids="35475">NSAID</z:chebi> use and risk of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We conducted a large population-based case-control study that collected information on patterns of intake for aspirin and non-aspirin <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> during the past 5 years and other exposures from 285 patients with nondysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, 108 patients with dysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, and two separate control groups: 313 endoscopy patients with <z:hpo ids='HP_0011009'>acute</z:hpo> inflammatory changes ('<z:mp ids='MP_0001845'>inflammation</z:mp> controls') and 644 population controls </plain></SENT>
<SENT sid="3" pm="."><plain>We calculated odds ratios (ORs) and 95% CIs using unconditional logistic regression </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Use of aspirin was not associated with nondysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> when compared with population (OR=1.01, 95% CI 0.71-1.43) or <z:mp ids='MP_0001845'>inflammation</z:mp> controls (OR=1.16, 95% CI 0.80-1.68) </plain></SENT>
<SENT sid="5" pm="."><plain>Whereas we observed significant risk reductions for use of non-aspirin <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> when nondysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> cases were compared with population controls (OR=0.69, 95% CI 0.49-0.97), the effect was weaker and nonsignificant when cases were compared with <z:mp ids='MP_0001845'>inflammation</z:mp> controls (OR=0.82, 95% CI 0.57-1.18), and no dose-response effects were present in either analysis </plain></SENT>
<SENT sid="6" pm="."><plain>We found no evidence that aspirin or non-aspirin <z:chebi fb="1" ids="35475">NSAID</z:chebi> use conferred risk reductions for dysplastic <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, regardless of the control series </plain></SENT>
<SENT sid="7" pm="."><plain>We excluded effect modification by known risk factors as an explanation for these null findings </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: We found little support for an inverse association between use of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The question of whether or not these medications prevent the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> remains open </plain></SENT>
</text></document>